Timothy D. Henry, MD
Dr. Timothy D. Henry is the Medical Director of The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital in Cincinnati, Ohio. Prior to The Lindner Research Center, he was the Chief of Cardiology at the Smidt Heart Institute at Cedars Sinai Medical Center and a Professor of Medicine at Cedars-Sinai and UCLA, the Director of Research at the Minneapolis Heart Institute Foundation, at Abbott Northwestern Hospital in Minneapolis and prior to that Director of Interventional Cardiology and the Cardiac Cath Lab at Hennepin County Medical Center.
He has published over 450 manuscripts and book chapters and has served on the Emergency Care Committee for the ACC, the AHA Mission: Lifeline Advisory Committee, the AHA Acute Cardiac Care Committee, ACC Interventional Subcommittee, and the Executive Committee for the Society for Cardiovascular Angiography and Interventions. His research interests include interventional cardiology, acute myocardial infarction, and novel therapies, including stem cell and gene therapy, for refractory angina patients who are not candidates for standard revascularization techniques.
He has served as principal investigator and steering committees of multiple large, multicenter research trials in acute myocardial infarction and refractory angina. He is the principal investigator for 1 of 7 NIH Clinical Cardiovascular Stem Cell Centers and has one of the largest research programs in the world for cardiovascular stem cell therapy. Among other awards, Henry has been named to the Best Doctors in America list each year between 2007 and 2019, became a Master Fellow for the Society for Cardiovascular Angioplasty and Interventions in 2015, received the American Heart Association’s Heart and Stroke Hero Award in Research in 2013 and was granted the LUMEN Global Lifetime Achievement Award in MI in 2012.
While members of the Medical Advisory Board are consulted to provide third party expert medical input into Triple-Gene’s product development efforts and clinical trial activities, they do not dictate or direct, nor are they responsible for, any development or clinical activities ultimately undertaken by Triple-Gene.